15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English 存档 1 PEG-Intron Plus Epivir-HBV
查看: 417|回复: 0

PEG-Intron Plus Epivir-HBV [复制链接]

Rank: 9Rank: 9Rank: 9

现金
101 元 
精华
帖子
3757 
注册时间
2002-10-6 
最后登录
2016-3-21 

荣誉之星

1
发表于 2003-9-8 05:09


Treatment for One Year with PEG-Intron Plus Epivir-HBV Has a Comparable Safety Profile to Short Term Use of Standard Interferon (Intron A)



Interferon alfa (IFN) treatment in chronic hepatitis B is associated with clinically relevant adverse effects. In an international, multicenter, randomized controlled trial in The Netherlands, investigators are studying the safety of PEG-Intron (peginterferon alfa-2b=PEG-IFN) in combination with Epivir-HBV (lamivudine).

Three-hundred HBeAg-positive patients (ALT>2xULN) with compensated liver disease were treated with PEG-IFN for 52 weeks, combined with either lamivudine 100mg/day or placebo. The dose of PEG-IFN was 100 mcg once a week and halved after 32 weeks.

As yet all patients have been treated for at least 32 weeks and 221 patients have finished treatment.

The most frequently encountered side-effects were flu-like symptoms (67%), headache (36%), myalgia (29%), fatigue (26%) and anorexia (25%). No deaths occurred during treatment or follow-up. A total of 24 (8%) serious adverse events were reported, of which 11 were regarded to be probably related to PEG-IFN (psychiatric n=5; neutropenia n=3; hepatitis flare n=2; seizures n=1).

In 55 (18%) patients the dose of PEG-IFN was reduced prematurely, in 39 (13%) because of a granulocytopenia. Therapy was discontinued early in 24 (8%) patients. The most frequent reasons for early discontinuation were psychiatric side effects (depression, psychosis) and flu-like symptoms. The number of side effects and the proportion of patients requiring dose reduction or interruption were similar to 162 historical controls treated with 10 MU t.i.w. of conventional IFN 10MU tiw for 16-32 weeks: IFN reduction 14% and IFN interruption 9% (Hepatology 1999;30: 238-43).

The researchers conclude that in compensated chronic hepatitis B (CHB) patients, prolonged PEG-IFN therapy has a comparable safety profile to short courses of conventional IFN therapy.

[B][color=17,203]Hbvers of all countries,unite![/B]
‹ 上一主题|下一主题

肝胆相照论坛

GMT+8, 2024-10-9 00:50 , Processed in 0.013780 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.